Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091864 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
A NA study of Glioblastoma, IDH-wildtype and WHO Grade 4 Glioma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT07091864 is a NA study of Glioblastoma, IDH-wildtype and WHO Grade 4 Glioma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 116 participants, below the 270-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07091864, a NA study of Glioblastoma, IDH-wildtype and WHO Grade 4 Glioma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy. Studies have shown that having a higher-than-normal amount of glucose in the blood (hyperglycemia) during radiation therapy is associated with poorer survival outcomes in glioblastoma patients. Hyperglycemia in glioblastoma patients is often driven by steroids that are commonly used during treatment. CGM uses a device that places a sensor under the skin that monitors glucose levels at regular intervals, providing real-time, or near real-time, glucose information. This can help to identify when a patient has changes in their glucose levels so they may receive necessary interventions or medications sooner. CGM may be an effective way for glioblastoma patients to manage their glucose levels, which may improve survival.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Best Practice
- OTHER Dietary Intervention
- OTHER Glucose Measurement
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2027-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091864
The ClinicalTrials.gov registry entry for NCT07091864 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (57% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma, IDH-wildtype appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07091864 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07091864 about?
NCT07091864 is a clinical study titled "Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma". This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximate...
What is the current status of trial NCT07091864?
This trial is currently recruiting. It is a NA study. The enrollment target is 116 participants. The study started on 2025-07-29. Estimated completion is 2027-11-30.
What conditions does trial NCT07091864 study?
This clinical trial studies the following conditions: Glioblastoma, IDH-wildtype, WHO Grade 4 Glioma.
What interventions are being tested in trial NCT07091864?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Best Practice (OTHER), Dietary Intervention (OTHER), Glucose Measurement (OTHER).
Who is sponsoring clinical trial NCT07091864?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091864 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma, IDH-wildtype
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RECRUITING
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
-
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RECRUITING
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.